Effectiveness and Safety Profile of Urethral Bulking with Bulkamid® for Stress Urinary Incontinence: A French Multi-Center Cohort Study
International Urogynecology Journal · 2025
DOI: 10.1007/s00192-024-06005-w ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Urogynecology Journal, 2025. Verfasst von Gery Lamblin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Gynecology Surgery Department, Hôpital Femme Mère Enfant, Bron, France. gery.lamblin@chu-lyon.fr. Hauptthemen laut MEDLINE: Urinary Incontinence, Stress, Urethra, Hyaluronic Acid, Dimethylpolysiloxanes. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Themen: Inkontinenz
Abstract (Originalsprache)
INTRODUCTION AND HYPOTHESIS: Various treatment options are currently available for the management of stress urinary incontinence (SUI). This study was aimed at determining the effectiveness and safety profile of Bulkamid®, and identify predictive factors of clinical success. METHODS: This retrospective study conducted in two French urogynecology university centers between September 2019 and December 2023 included all patients with urinary incontinence who received Bulkamid®. RESULTS: Among the 320 patients included (median age 58.2 years), the median follow-up was 24 months. Urethral hypermobility was found in 93.4% of patients (n = 282) and 92% (n = 275) had a positive cough test. At 1 month, 68.7% of patients (n = 220) achieved clinical success, 25.6% (n = 82) improved, and 5.6% (n = 18) reported failure. At last follow-up, 63.7% of patients (n = 204) were still cured, 21.9% (n = 70) had improved, and 14.4% (n = 46) reported failure. Among the 16 patients with overactive bladder (OAB) 43.7% had a Patient Global Improvement (PGI) score of 1-2 at 1 month and 50.0% at last follow-up, with significant difference compared with patients without OAB, 81.0% had a PGI score of 1-2 at 1 month and 74.8% at last follow-up (p = 0.0006 and p = 0.04 respectively). Regarding complications, acute urinary retention occurred in 3.1% of patients (n = 10), urinary infections in 2.2% (n = 7), and transient hematuria in 7.2% (n = 23). In multivariate analysis, follow-up time was significantly associated with failure compared with improvement/cure (OR = 1.05, 95% CI 1.02-1.08, p = 0.0002). CONCLUSION: The present large series of patients reported the effectiveness of Bulkamid® injection, a minimally invasive procedure providing good clinical outcomes at 2 years' follow-up.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gynecology Surgery Department, Hôpital Femme Mère Enfant, Bron, France. gery.lamblin@chu-lyon.fr.
- Université Claude Bernard Lyon 1, Lyon, France. gery.lamblin@chu-lyon.fr.
- Department of Gynecology Surgery, Femme Mere Enfant University Hospital, 59 Boulevard Pinel, 69677, Lyon-Bron, France. gery.lamblin@chu-lyon.fr.
- Gynecology Surgery Department, Hôpital Femme Mère Enfant, Bron, France.
- Clinique Sainte Barbe, Groupe Hospitalier Saint Vincent, Strasbourg, France.
ORCID-Profile: Gery Lamblin
Zitieren
APA
Lamblin, G., Boix, S., Moret, S., Nohuz, E., Chene, G., & Hamid, D. (2025). Effectiveness and Safety Profile of Urethral Bulking with Bulkamid® for Stress Urinary Incontinence: A French Multi-Center Cohort Study. International Urogynecology Journal. https://doi.org/10.1007/s00192-024-06005-w
Vancouver
Lamblin G, Boix S, Moret S, Nohuz E, Chene G, Hamid D. Effectiveness and Safety Profile of Urethral Bulking with Bulkamid® for Stress Urinary Incontinence: A French Multi-Center Cohort Study. International Urogynecology Journal. 2025. doi:10.1007/s00192-024-06005-w
BibTeX
@article{Lamblin2025,
author = {Lamblin, Gery and Boix, Solene and Moret, Stéphanie and Nohuz, Erdogan and Chene, Gautier and Hamid, David},
title = {Effectiveness and Safety Profile of Urethral Bulking with Bulkamid® for Stress Urinary Incontinence: A French Multi-Center Cohort Study},
journal = {International Urogynecology Journal},
year = {2025},
doi = {10.1007/s00192-024-06005-w}
}
EUVIMED